Regeneron Pharmaceuticals Inc.
Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years[...]
06/20/2024 | Press release | Distributed by Public on 06/20/2024 07:24
Please select the service you want to use:
Smartlinks | Purple Biotech Ltd. | News | Crime and Judiciary | Judiciary | Health | Finance | Security Markets | Security Markets | Company News | Business Announcement | Corporate Litigation and Regulation | Investment Funds | Judiciary | Securities Issuers | Biotechnology and Medical Research Companies | Frankfurt Stock Exchange | Tel Aviv Stock Exchange (TASE) | Berlin Stock Exchange | Dusseldorf Stock Exchange | Munich Stock Exchange | Stuttgart Stock Exchange | OTC Markets | Tradegate Exchange | NYSE American | NYSE ARCA Equities | Nasdaq Capital Market | Cboe BZX Exchange | Cboe BYX Exchange | Cboe EDGA Exchange | Cboe EDGX Exchange | NYSE National | FINRA Alternative Display Facility (ADF) | Nasdaq BX | Nasdaq PSX | NYSE Chicago
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact